Christine E Chaisson
Biographic Data
| ID | 5535598 |
|---|---|
| NAME | Christine E Chaisson |
| GIVEN NAMES | Christine E |
| FAMILY NAME | Chaisson |
| SIGNATURE | CHAISSON C E |
| AFFILIATIONS | Boston University |
| ORCID | 0000-0002-3207-9257 |
| VERIFIED | Yes |
| TOTAL WORKS | 8 |
| TOTAL CITATIONS | 0 |
| AUTHOR COUNT | 8 |
| EDITOR COUNT | 0 |
| FIRST PUBLICATION YEAR | 2012 |
| LATEST PUBLICATION YEAR | 2022 |
| H-INDEX | 0 |
Variation in Initiation, Engagement, and Retention on Medications for Opioid Use Disorder Based on Health Insurance Plan Design
BACKGROUND: The association between cost-sharing and receipt of medication for opioid use disorder (MOUD) is unknown. METHODS: We constructed a cohort of 10,513 commercially insured individuals with a new diagnosis of opioid use disorder and information on insurance cost-sharing in a large national deidentified claims database. We examined 4 cost-sharing measures: (1) pharmacy deductible; (2) medical service deductible; (3) pharmacy medication co…
Quality of Buprenorphine Care for Insured Adults With Opioid Use Disorder
AIM: The aim of this study was to characterize quality of buprenorphine care for opioid use disorder (OUD) by quantifying buprenorphine initiation, engagement, and maintenance for individuals in a large, diverse, real-world cohort in the United States. DESIGN: This was a retrospective cohort analysis. SETTING: OUD treatment in the outpatient setting. PARTICIPANTS: A total of 45,210 commercially insured and Medicare Advantage (MA) enrollees 18 yea…
Comparative Effectiveness of Different Treatment Pathways for Opioid Use Disorder
Importance Although clinical trials demonstrate the superior effectiveness of medication for opioid use disorder (MOUD) compared with nonpharmacologic treatment, national data on the comparative effectiveness of real-world treatment pathways are lacking. Objective To examine associations between opioid use disorder (OUD) treatment pathways and overdose and opioid-related acute care use as proxies for OUD recurrence. Design, Setting, and Participa…
Relative Cost Differences of Initial Treatment Strategies for Newly Diagnosed Opioid Use Disorder
BACKGROUND: Relative costs of care among treatment options for opioid use disorder (OUD) are unknown. METHODS: We identified a cohort of 40,885 individuals with a new diagnosis of OUD in a large national de-identified claims database covering commercially insured and Medicare Advantage enrollees. We assigned individuals to 1 of 6 mutually exclusive initial treatment pathways: (1) Inpatient Detox/Rehabilitation Treatment Center; (2) Behavioral Hea…
HIV Stigma and Substance Use Among HIV-Positive Russians with Risky Drinking
Fatal and non-fatal overdose after narcology hospital discharge among Russians living with HIV/Aids who inject drugs
Risk factors for recent nonfatal overdose among HIV-infected Russians who inject drugs
Overdoses and HIV infection are common among Russians who inject drugs, yet risk factors have not been studied. We analyzed baseline data of 294 participants with 30-day injection drug use from an HIV secondary prevention trial for persons reporting "heavy" alcohol use (National Institute on Alcohol Abuse and Alcoholism [NIAAA] risky drinking definition) and risky sex in the past 6 months. The outcome was any self-reported overdose in the previou…
Nondisclosure of HIV Infection to Sex Partners and Alcohol’s Role
No prominent works on this page.
Nondisclosure of HIV Infection to Sex Partners and Alcohol’s Role
Risk factors for recent nonfatal overdose among HIV-infected Russians who inject drugs
Overdoses and HIV infection are common among Russians who inject drugs, yet risk factors have not been studied. We analyzed baseline data of 294 participants with 30-day injection drug use from an HIV secondary prevention trial for persons reporting "heavy" alcohol use (National Institute on Alcohol Abuse and Alcoholism [NIAAA] risky drinking definition) and risky sex in the past 6 months. The outcome was any self-reported overdose in the previou…
HIV Stigma and Substance Use Among HIV-Positive Russians with Risky Drinking
Fatal and non-fatal overdose after narcology hospital discharge among Russians living with HIV/Aids who inject drugs
Comparative Effectiveness of Different Treatment Pathways for Opioid Use Disorder
Importance Although clinical trials demonstrate the superior effectiveness of medication for opioid use disorder (MOUD) compared with nonpharmacologic treatment, national data on the comparative effectiveness of real-world treatment pathways are lacking. Objective To examine associations between opioid use disorder (OUD) treatment pathways and overdose and opioid-related acute care use as proxies for OUD recurrence. Design, Setting, and Participa…
Relative Cost Differences of Initial Treatment Strategies for Newly Diagnosed Opioid Use Disorder
BACKGROUND: Relative costs of care among treatment options for opioid use disorder (OUD) are unknown. METHODS: We identified a cohort of 40,885 individuals with a new diagnosis of OUD in a large national de-identified claims database covering commercially insured and Medicare Advantage enrollees. We assigned individuals to 1 of 6 mutually exclusive initial treatment pathways: (1) Inpatient Detox/Rehabilitation Treatment Center; (2) Behavioral Hea…
Quality of Buprenorphine Care for Insured Adults With Opioid Use Disorder
AIM: The aim of this study was to characterize quality of buprenorphine care for opioid use disorder (OUD) by quantifying buprenorphine initiation, engagement, and maintenance for individuals in a large, diverse, real-world cohort in the United States. DESIGN: This was a retrospective cohort analysis. SETTING: OUD treatment in the outpatient setting. PARTICIPANTS: A total of 45,210 commercially insured and Medicare Advantage (MA) enrollees 18 yea…
Variation in Initiation, Engagement, and Retention on Medications for Opioid Use Disorder Based on Health Insurance Plan Design
BACKGROUND: The association between cost-sharing and receipt of medication for opioid use disorder (MOUD) is unknown. METHODS: We constructed a cohort of 10,513 commercially insured individuals with a new diagnosis of opioid use disorder and information on insurance cost-sharing in a large national deidentified claims database. We examined 4 cost-sharing measures: (1) pharmacy deductible; (2) medical service deductible; (3) pharmacy medication co…
HIV, Drug Use, Sexual Risk (7 works) · Medicine (7 works) · Opioid Use Disorder Treatment (5 works) · HIV/AIDS Research and Interventions (4 works) · Internal Medicine (4 works) · Opioid use disorder (4 works) · Buprenorphine (3 works) · Cohort (3 works) · Cohort study (3 works) · Emergency Medicine (3 works)